Intra-Cellular Therapies' CAPLYTA is making waves in the antipsychotic market, gaining traction as a novel treatment for schizophrenia and bipolar de ...

MIT neuroscientists have made a breakthrough in treating fragile X syndrome by leveraging a novel neurotransmitter signaling ...

MIT researchers suggests a potential molecular strategy for treating fragile X syndrome by enhancing NMDA subunit function.

Building on more than two decades of research, a study by MIT neuroscientists at The Picower Institute for Learning and Memory reports a new way to treat pathology and symptoms of fragile X syndrome, ...

Researchers at the University of Illinois have found a direct link between a genetic mutation and schizophrenia. The ...

A genetic mutation found in two human patients with schizophrenia also increased schizophrenia-related behaviors in mice with ...

Agriculture departments in New Mexico and Texas are again warning residents about potentially dangerous "foreign seeds" arriving in unsolicited packages. "If you receive a package of seeds that you ...

Ketamine, a non-competitive N-methyl-D-aspartate receptor antagonist, has emerged as an effective therapeutic agent for the management of treatment-resistant depression. Repeated treatments with ...